课题基金 / 基金详情

项目摘要

项目成果

Eva M. Sevick-Muraca的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The administrative core with key clinical investigators from each participating clinical site will compile and submit FDA and harmonized IRB applications for approval. Dr. Sevick will be responsible for making the technologies available and overseeing overall execution of the primary project; Dr. Marshall will oversee regulatory and compliance aspects, and Dr. Berger along with participating clinicians will ensure patient safety and proper clinical trial design. Figure 2 illustrates the overall structure of the NTR team with the primary focus on clinical application of technologies to nodal staging of melanoma and breast cancer in Nuclear Medicine, the Operating Room, and Pathology. Task Specific Projects #1-4 and all Cores are housed within the Division of Molecular Imaging, of which Dr. Sevick is Division Head. Efforts demarked by a dashed box represent leveraged contributions provided without cost to the NTR. The administrative core comprised of Drs. Sevick, Marshall, and Berger will oversee all aspects of the NTR project, including technology deployment, compliance, and patient care and safety. Breast Center faculty (Chang, Gutierrez), Nuclear Medicine faculty (Wendt), Surgery faculty (Bonefas) who have clinical privileges at BTGH will assume patient care responsibilities in their specialty areas. Faculty with clinical privileges at the MEDVAMC in surgery (Berger, Albo), nuclear medicine (Bhargava) and pathology (Ittmann) will also assume patient care responsibilities in their specialty area. The Dan L. Duncan Cancer Center Clinical Trials Support Unit will assist in compliance activities and conduct audits to ensure adequate safety safeguards are in place during clinical studies. Quality assurance for GLP-compliant studies will fall under the Administrative Core, as will Quality Control for manufacturing procedures.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Assessing CSF flow dynamics in pediatric hemorrhagic hydrocephalus
Lymphatic delivery of immunotherapy to prevent irAEs
Assessing CSF flow dynamics in pediatric hemorrhagic hydrocephalus
Lymphatic delivery of immunotherapy to prevent irAEs
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
  • 批准号:
    2021JJ40433
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
    孙磊
  • 依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
  • 批准号:
    32001603
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    段真珍
  • 依托单位:
AREA国际经济模型的移植.改进和应用
  • 批准号:
    18870435
  • 项目类别:
    面上项目
  • 资助金额:
    2.0万元
  • 批准年份:
    1988
  • 负责人:
    史树中
  • 依托单位: